Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,009
Employees3,009
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,009
Employees3,009

HAE Key Statistics

Market cap
5.48B
Market cap5.48B
Price-Earnings ratio
54.97
Price-Earnings ratio54.97
Dividend yield
—
Dividend yield—
Average volume
619.76K
Average volume619.76K
High today
$123.96
High today$123.96
Low today
$119.37
Low today$119.37
Open price
$123.96
Open price$123.96
Volume
426.26K
Volume426.26K
52 Week high
$132.00
52 Week high$132.00
52 Week low
$51.00
52 Week low$51.00

Stock Snapshot

As of today, Haemonetics(HAE) shares are valued at $120.37. The company's market cap stands at 5.48B, with a P/E ratio of 54.97.

On 2026-11-20, Haemonetics(HAE) stock traded between a low of $119.37 and a high of $123.96. Shares are currently priced at $120.37, which is +0.8% above the low and -2.9% below the high.

Haemonetics(HAE) shares are trading with a volume of 426.26K, against a daily average of 619.76K.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $132.00 and a 52-week low of $51.00.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $132.00 and a 52-week low of $51.00.

HAE News

Investing.com 2d
Haemonetics receives CE mark for vascular closure system - Investing.com

...

Haemonetics receives CE mark for vascular closure system - Investing.com
TipRanks 4d
Haemonetics price target raised to $144 from $115 at Citizens

Citizens raised the firm’s price target on Haemonetics (HAE) to $144 from $115 and keeps an Outperform rating on the shares. Haemonetics delivered broad-based s...

Simply Wall St 6d
What Haemonetics Stock's Raised Guidance Means For Shareholders

Haemonetics reported second quarter fiscal 2027 sales of US$357.76 million and net income of US$46.31 million, raised full year 2027 revenue guidance to 8% to 1...

What Haemonetics Stock's Raised Guidance Means For Shareholders

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

More HAE News

Simply Wall St 7d
Haemonetics Lifts 2027 Guidance Following Q2 Earnings, Is It Fully Priced?

Haemonetics earnings and guidance reset the story Haemonetics (HAE) has investors’ attention after second quarter results showed higher sales and profit than a...

Haemonetics Lifts 2027 Guidance Following Q2 Earnings, Is It Fully Priced?

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.